Lantheus Holdings, Inc. (FRA:0L8)

Market Cap	4.16B -31.1%
Revenue (ttm)	1.30B +1.9%
Net Income	142.91M -60.8%
EPS	2.04 -60.3%
Shares Out	n/a
PE Ratio	29.09
Forward PE	13.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	61.80
Previous Close	61.42
Day's Range	61.80 - 61.80
52-Week Range	41.91 - 100.25
Beta	n/a
RSI	71.03
Earnings Date	Feb 26, 2026

About Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1956
• Employees: 808
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0L8

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.

Financial numbers in USD